MX2020002077A - Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentradas, kits y metodos para el tratamiento de sujetos que padecen sindrome hemolitico atipico. - Google Patents
Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentradas, kits y metodos para el tratamiento de sujetos que padecen sindrome hemolitico atipico.Info
- Publication number
- MX2020002077A MX2020002077A MX2020002077A MX2020002077A MX2020002077A MX 2020002077 A MX2020002077 A MX 2020002077A MX 2020002077 A MX2020002077 A MX 2020002077A MX 2020002077 A MX2020002077 A MX 2020002077A MX 2020002077 A MX2020002077 A MX 2020002077A
- Authority
- MX
- Mexico
- Prior art keywords
- kits
- methods
- subjects suffering
- low viscosity
- treating subjects
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 230000002949 hemolytic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 abstract 2
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract 1
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550328P | 2017-08-25 | 2017-08-25 | |
| PCT/US2018/047255 WO2019040453A1 (en) | 2017-08-25 | 2018-08-21 | HIGHLY CONCENTRATED MASP-2 INHIBITOR ANTIBODY FORMULATIONS WITH LOW VISCOSITY, KITS AND METHODS FOR TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002077A true MX2020002077A (es) | 2020-03-24 |
Family
ID=65436837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002077A MX2020002077A (es) | 2017-08-25 | 2018-08-21 | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentradas, kits y metodos para el tratamiento de sujetos que padecen sindrome hemolitico atipico. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190062455A1 (enExample) |
| EP (1) | EP3672994A4 (enExample) |
| JP (1) | JP2020531523A (enExample) |
| KR (1) | KR20200037863A (enExample) |
| CN (1) | CN111278863A (enExample) |
| AU (1) | AU2018322032B2 (enExample) |
| BR (1) | BR112020003632A2 (enExample) |
| CA (1) | CA3072913A1 (enExample) |
| CL (1) | CL2020000397A1 (enExample) |
| IL (1) | IL272673B2 (enExample) |
| MA (1) | MA49960A (enExample) |
| MX (1) | MX2020002077A (enExample) |
| RU (1) | RU2020111574A (enExample) |
| TW (1) | TW201925224A (enExample) |
| WO (1) | WO2019040453A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4057980A1 (en) * | 2019-11-15 | 2022-09-21 | F. Hoffmann-La Roche AG | Prevention of visible particle formation in aqueous protein solutions |
| TW202135860A (zh) * | 2019-12-10 | 2021-10-01 | 美商再生元醫藥公司 | 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
| WO2022026914A1 (en) * | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| US20230416406A1 (en) * | 2022-03-10 | 2023-12-28 | Omeros Corporation | Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101875155B1 (ko) * | 2011-05-02 | 2018-07-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| EP2704743B1 (en) * | 2011-05-04 | 2020-03-11 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
| CN118924900A (zh) * | 2012-06-18 | 2024-11-12 | 奥默罗斯公司 | 抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
| WO2015058143A1 (en) * | 2013-10-17 | 2015-04-23 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| WO2016094834A2 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
| SG10202011469UA (en) * | 2015-11-09 | 2020-12-30 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
-
2018
- 2018-08-21 US US16/106,986 patent/US20190062455A1/en not_active Abandoned
- 2018-08-21 IL IL272673A patent/IL272673B2/en unknown
- 2018-08-21 EP EP18847767.3A patent/EP3672994A4/en not_active Withdrawn
- 2018-08-21 BR BR112020003632-3A patent/BR112020003632A2/pt unknown
- 2018-08-21 JP JP2020511307A patent/JP2020531523A/ja active Pending
- 2018-08-21 WO PCT/US2018/047255 patent/WO2019040453A1/en not_active Ceased
- 2018-08-21 CN CN201880054825.8A patent/CN111278863A/zh active Pending
- 2018-08-21 CA CA3072913A patent/CA3072913A1/en active Pending
- 2018-08-21 AU AU2018322032A patent/AU2018322032B2/en active Active
- 2018-08-21 MX MX2020002077A patent/MX2020002077A/es unknown
- 2018-08-21 KR KR1020207008257A patent/KR20200037863A/ko not_active Ceased
- 2018-08-21 RU RU2020111574A patent/RU2020111574A/ru unknown
- 2018-08-21 MA MA049960A patent/MA49960A/fr unknown
- 2018-08-22 TW TW107129307A patent/TW201925224A/zh unknown
-
2020
- 2020-02-18 CL CL2020000397A patent/CL2020000397A1/es unknown
-
2023
- 2023-10-04 US US18/480,825 patent/US20240247078A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020003632A2 (pt) | 2020-10-27 |
| CL2020000397A1 (es) | 2020-07-10 |
| US20190062455A1 (en) | 2019-02-28 |
| MA49960A (fr) | 2021-06-02 |
| IL272673B1 (en) | 2024-06-01 |
| RU2020111574A3 (enExample) | 2021-11-17 |
| KR20200037863A (ko) | 2020-04-09 |
| TW201925224A (zh) | 2019-07-01 |
| AU2018322032A1 (en) | 2020-03-12 |
| RU2020111574A (ru) | 2021-09-27 |
| US20240247078A1 (en) | 2024-07-25 |
| JP2020531523A (ja) | 2020-11-05 |
| IL272673A (en) | 2020-03-31 |
| AU2018322032B2 (en) | 2025-04-17 |
| WO2019040453A1 (en) | 2019-02-28 |
| CN111278863A (zh) | 2020-06-12 |
| CA3072913A1 (en) | 2019-02-28 |
| IL272673B2 (en) | 2024-10-01 |
| EP3672994A4 (en) | 2021-06-02 |
| EP3672994A1 (en) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500365A1 (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| SA519402159B1 (ar) | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها | |
| JOP20200309A1 (ar) | أجسام مضادة لـ il-11 | |
| AU2018263868A1 (en) | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies | |
| PH12018500684A1 (en) | Agonistic antibodies specifically binding human cd40 and methods of use | |
| PH12019502025A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| JO3772B1 (ar) | صيغة جسم مضاد لـ cgrp | |
| PH12017501522B1 (en) | Antibodies to tau and uses thereof | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| MX2020002077A (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentradas, kits y metodos para el tratamiento de sujetos que padecen sindrome hemolitico atipico. | |
| AU2016348418A8 (en) | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same | |
| MY199876A (en) | Anti-pacap antibody | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| JOP20190100A1 (ar) | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها | |
| CR20220322A (es) | Formulaciones de anticuerpos anti-pd-l1 | |
| EA202090971A1 (ru) | Способы применения и композиции, содержащие дулаглутид | |
| MX2022009130A (es) | Anticuerpos anti-e-selectina, composiciones y metodos de uso. | |
| PH12021550607A1 (en) | Antibodies and methods for treatment of lyssavirus infection | |
| EA202192418A1 (ru) | Способы лечения al-амилоидоза | |
| EA201990824A1 (ru) | Антитела, которые связываются с интерлейкином-2, и их применение |